ZOLGENSMA: The one-time-only dose to stop SMA progression1

Study designs for ongoing and completed ZOLGENSMA clinical trials
A phase 3, ongoing clinical trial
A completed, phase 1, ascending-dose trial
A 15-year, voluntary follow-up of patients from the START trial